Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
09/2000
09/06/2000EP1032678A1 Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity
09/06/2000EP1032671A1 Mammalian cytokine-like polypeptide-10
09/06/2000EP1032667A2 A33-related antigens and their pharmacological uses
09/06/2000EP1032664A2 HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
09/06/2000EP1032662A1 Methods and compositions for immunomodulation
09/06/2000EP1032659A1 Grafted copolymers as gene carriers
09/06/2000EP1032595A2 Nucleic acids involved in the responder phenotype and applications thereof
09/06/2000EP1032582A1 NOVEL recJ
09/06/2000EP1032429A1 A method for in vivo dna delivery using a needle free apparatus
09/06/2000EP1032428A2 Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
09/06/2000EP1032423A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
09/06/2000EP1032420A1 Immunoglobulin molecules having a synthetic variable region and modified specificity
09/06/2000EP1032418A1 Compact epstein-barr virus replicons
09/06/2000EP1032369A1 Targeted liposome gene delivery
09/06/2000EP1032271A1 Purging of stem cell products
09/06/2000EP1032269A1 Treatment of neoplasms with viruses
09/06/2000CN1265600A Cloning pigs using donor nuclei from differentiated cells
09/06/2000CN1265599A Cloning using donor nuclei from non-serum starved, differentiated cells
09/05/2000US6114599 Producing glucose regulated insulin producing cells whose proliferation is regulated by tetracycline; introducing into cells a tetracycline fusion protein gene, an insulin promoter and a gene encoding an sv40 antigen and tetracycline promoter
09/05/2000US6114517 Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
09/05/2000US6114515 PIGRL-1, a member of immunoglobulin gene superfamily
09/05/2000US6114513 Medical diagnosis; transfer across cell membranes
09/05/2000US6114311 Administering an adenviral compound
09/05/2000US6114141 Contacting host cell with conditionally replicating virus vector and a wild-type virus, a helper virus, or a helper vector; then expressing gene; prophylactic and therapeutic treatment of human immunodeficiency virus
09/05/2000US6114109 Viral (HIV) growth inhibition
09/05/2000US6113946 Self-assembling polynucleotide delivery system comprising dendrimer polycations
09/05/2000US6113913 Genomes and gene codes
09/05/2000US6113905 Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases
09/05/2000US6113903 Antidiabetic agents
09/05/2000US6113902 Polypeptides with amino acid sequences of pro-lys-ile and cyclic epitopes
09/05/2000CA2298892A1 Lentiviral vectors derived from sivagm, methods for their preparation and their use for gene transfer into mammalian cells
09/05/2000CA2186122C C-terminally truncated cftr genes and proteins
08/2000
08/31/2000WO2000050638A1 Diagnosis and therapy of premature ovarian failure
08/31/2000WO2000050637A1 Identification of genes having a role in the presentation of diabetic nephropathy
08/31/2000WO2000050619A1 Adenovirus mutants with deleted protease gene, complementing cell lines and corresponding vectors for gene transfer
08/31/2000WO2000050618A1 Virus vector
08/31/2000WO2000050617A1 Intravascular delivery of non-viral nucleic acid
08/31/2000WO2000050602A1 Tdk polypeptides and polynucleotides and methods thereof
08/31/2000WO2000050595A2 Nucleic acid molecules associated with melanoma and thyroid tumors
08/31/2000WO2000050590A1 Mdm interacting protein and methods of use thereof
08/31/2000WO2000050588A2 Genes associated with diseases of the colon
08/31/2000WO2000050584A2 Methods and compositions for enhancing in vivo gene delivery/expression
08/31/2000WO2000050580A2 Composition, methods and reagents for the synthesis of a soluble form of human phex
08/31/2000WO2000050571A1 Improved method of culturing t cells
08/31/2000WO2000050568A2 Transplantation of haematopoietic cells
08/31/2000WO2000050565A2 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene
08/31/2000WO2000050562A2 Dna encoding snorf25 receptor
08/31/2000WO2000050458A1 Cloning of a p2y-like 7tm receptor (axor17)
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050070A2 Preparation for the treatment of pigmentation disorders
08/31/2000WO2000050062A2 Methods and compositions for altering mucus secretion
08/31/2000WO2000050050A1 Multiparticulate formulation
08/31/2000WO2000050049A2 Artificial salivary gland
08/31/2000WO2000050008A2 Antibody fragment-targeted immunoliposomes for systemic gene delivery
08/31/2000WO2000049937A2 Trpm-2 antisense therapy
08/31/2000WO2000036113A3 Extending graft survival by heme oxygenase-i expression induced immunomodulation
08/31/2000WO2000028038A3 Virulence genes and proteins, and their use
08/31/2000WO2000023112A9 Modulation of gene expression by combination therapy
08/31/2000WO2000018910A9 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
08/31/2000WO2000018795A9 Compositions and methods for wt1 specific immunotherapy
08/31/2000CA2850318A1 Trpm-2 antisense therapy
08/31/2000CA2371814A1 Trpm-2 antisense therapy
08/31/2000CA2366951A1 Methods and compositions for altering mucus secretion
08/31/2000CA2365094A1 Composition, methods and reagents for the synthesis of a soluble form of human phex
08/31/2000CA2365089A1 Identification of genes having a role in the presentation of diabetic nephropathy
08/31/2000CA2365026A1 Virus vector
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363106A1 Mdm interacting protein and methods of use thereof
08/31/2000CA2362906A1 Dna encoding snorf25 receptor
08/31/2000CA2361743A1 Genes associated with diseases of the colon
08/31/2000CA2361401A1 Transplantation of haematopoietic cells
08/31/2000CA2361396A1 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene
08/30/2000EP1030935A1 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
08/30/2000EP1030929A1 Transfection and transfer of male germ cells for generation of transgenic species
08/30/2000EP1030928A1 Development of viruses resistant to inactivation by the human complement system
08/30/2000EP1030925A1 The translation enhancer element of the human amyloid precursor protein gene
08/30/2000EP1030923A2 Method for producing virus-like particles on the basis of polyoma viruses
08/30/2000EP1030919A2 Cdk2 protein and cdk2 protein complexes
08/30/2000EP1030917A1 Transcriptionally regulated g protein-coupled receptor
08/30/2000EP1030916A2 Differentially expressed genes in cardiac hypertrophy and their uses in treatment and diagnosis
08/30/2000EP1030915A1 A novel gene and uses therefor
08/30/2000EP1030914A2 Antisense oligonucleotides against tenascin for treating vitiligo
08/30/2000EP1030908A1 Genetically-modified myogenic progenitors and their use in cell and gene therapy
08/30/2000EP1030866A2 Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids
08/30/2000EP1030690A1 Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype
08/30/2000EP1030684A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
08/30/2000EP1030683A1 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
08/30/2000EP1030681A1 Method and compositions for inhibiting angiogenesis and treating cancer
08/30/2000EP1030680A1 Treatment of kaposi's sarcoma with il-12
08/30/2000EP1030656A1 Administering active substances by using the capsid produced out of the polyoma virus vp1 protein
08/30/2000EP1030557A1 Protein delivery by secretory gland expression
08/30/2000EP0584287B1 Purification of müllerian inhibiting substance for treatment of certain tumors
08/30/2000CN1265149A Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
08/30/2000CN1265148A Anticoagulant fusion protein anchored to cell membrane
08/30/2000CN1055968C Colon bacillus cytosine ammonialyse gene and new substance containing same
08/29/2000US6111095 Capped synthetic RNA, analogs, and aptamers
08/29/2000US6111094 Enhanced antisense modulation of ICAM-1
08/29/2000US6111085 Carbamate-derivatized nucleosides and oligonucleosides
08/29/2000US6111078 Staphylococcus aureus rsbU-1
08/29/2000US6111076 Human G-protein coupled receptor (HIBCD07)
1 ... 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 ... 870